NCT00791778 - Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

246

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

December 31, 2012

Conditions

Ovarian Neoplasms

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.

DRUG

Placebo

Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.

Trial Locations (59)

1000

Bruxelles - Brussel

1200

Bruxelles - Brussel

2610

Wilrijk

2650

Edegem

3000

Leuven

7100

La Louvière

13353

Berlin

14076

Caen

20141

Milan

27003

Lugo

28040

Madrid

28041

Madrid

30912

Augusta

32209

Jacksonville

37044

Tours

39373

Lyon

41013

Seville

47014

Meldola

49933

Angers

92037

La Jolla

94805

Villejuif

119228

Singapore

229899

Singapore

04074

Scarborough

L8V 5C2

Hamilton

N6A 4L6

London

M5G 2M9

Toronto

H2L 4M1

Montreal

FI-40620

Jyväskylä

FIN- 70211

Kuopio

Unknown

Hong Kong

Lublin

00168

Campobasso

Roma

00167

Roma

464-8681

Nagoya

277-8567

Kashiwa

259-1193

Isehara

329-0498

Shimotsuke

135-8550

Koto-ku

105-8471

Minato-ku

6229 HX

Maastricht

2545 CH

The Hague

15-027

Bialystok

81-519

Gdynia

31-115

Krakow

61-866

Poznan

61-878

Poznan

02-781

Warsaw

110-744

Seoul

700-712

Daegu

410-769

Gyeonggi-do

405-760

Incheon

120-752

Seoul

135-710

Seoul

138-736

Seoul

158-710

Seoul

443-721

Sŏwŏn

08208

Sabadell